Joao Zulaica

Joao Zulaica

Auto-generated profile, based on publicly available information

Joao Zulaica

Instituto Biofisika (UPV/EHU, CSIC), University of the Basque Country, Leioa, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Computers in Biology and Medicine
Verified
Journal Article
Open access
AAAna Isabel Avilés-Alía
Ana Isabel Avilés-Alía
JZJoao Zulaica
Joao Zulaica
JPJuan J. Perez
Juan J. Perez
JRJaime Rubio-Martinez
Jaime Rubio-Martinez
RGRon Geller
Ron Geller
JGJose M. Granadino-Roldan
Jose M. Granadino-Roldan
SARS-CoV-2 must bind its principal receptor, ACE2, on the target cell to initiate infection. This interaction is largely driven by the receptor binding domain (RBD) of the viral Spike (S) protein. Accordingly, antiviral compounds that can block RBD/ACE2 interactions can constitute promising antiviral agents. To identify such molecules, we performed a virtual screening of the Selleck FDA approved drugs and the Selleck database of Natural Products using a multistep computational procedure. An initial set of candidates was identified from an ensemble docking process using representative structures determined from the analysis of four 3 μ s molecular dynamics trajectories of the RBD/ACE2 complex. Two procedures were used to construct an initial set of candidates including a standard and a pharmacophore guided docking procedure. The initial set was subsequently subjected to a multistep sieving process to reduce the number of candidates to be tested experimentally, using increasingly demanding computational procedures, including the calculation of the binding free energy computed using the MMPBSA and MMGBSA methods. After the sieving process, a final list of 10 candidates was proposed, compounds which were subsequently purchased and tested ex-vivo. The results identified estradiol cypionate and telmisartan as inhibitors of SARS-CoV-2 entry into cells. Our findings demonstrate that the methodology presented here enables the discovery of inhibitors targeting viruses for which high-resolution structures are available.

15 November 2023 in Plant Biotechnology Journal
Verified
Journal Article
Open access
FMFernando Merwaiss
Fernando Merwaiss
ELEnrique Lozano‐Sanchez
Enrique Lozano‐Sanchez
JZJoão Zulaica
João Zulaica
LRLuciana Rusu
Luciana Rusu
MVMarta Vazquez-Vilar
Marta Vazquez-Vilar
JDJosé-Antonio Daròs
José-Antonio Daròs
Summary: Viral nanoparticles (VNPs) are a new class of virus‐based formulations that can be used as building blocks to implement a variety of functions of potential interest in biotechnology and nanomedicine. Viral coat proteins (CP) that exhibit self‐assembly properties are particularly appropriate for displaying antigens and antibodies, by generating multivalent VNPs with therapeutic and diagnostic potential. Here, we developed genetically encoded multivalent VNPs derived from two filamentous plant viruses, potato virus X (PVX) and tobacco etch virus (TEV), which were efficiently and inexpensively produced in the biofactory Nicotiana benthamiana plant. PVX and TEV‐derived VNPs were decorated with two different nanobodies recognizing two different regions of the receptor‐binding domain (RBD) of the SARS‐CoV‐2 Spike protein. The addition of different picornavirus 2A ribosomal skipping peptides between the nanobody and the CP allowed for modulating the degree of VNP decoration. Nanobody‐decorated VNPs purified from N. benthamiana tissues successfully recognized the RBD antigen in enzyme‐linked immunosorbent assays and showed efficient neutralization activity against pseudoviruses carrying the Spike protein. Interestingly, multivalent PVX and TEV‐derived VNPs exhibited a neutralizing activity approximately one order of magnitude higher than the corresponding nanobody in a dimeric format. These properties, combined with the ability to produce VNP cocktails in the same N. benthamiana plant based on synergistic infection of the parent PVX and TEV, make these green nanomaterials an attractive alternative to standard antibodies for multiple applications in diagnosis and therapeutics.

25 November 2025 in Communications Biology
Verified
Journal Article
Open access
Izaskun MorilloIzaskun Morillo
Izaskun Morillo
JZJoao Zulaica
Joao Zulaica
ACAsier R. Caballero
Asier R. Caballero
JAJaione Auzmendi-Iriarte
Jaione Auzmendi-Iriarte
ELEneko Largo
Eneko Largo
EREdurne Rujas
Edurne Rujas
Pore-forming peptides (PFPs) hold strong anti-tumor potential but require delivery systems to ensure stability and prevent off-target effects. In this study, we develop a strategy to transport a PFP in a biologically latent, precursor-like state. Specifically, based on the therapeutic antibody atezolizumab, which targets the tumor-associated programmed death-ligand 1, we engineered a single-chain IgG (scIgG) construct with flexible linkers embedding the melittin sequence. To further enable tumor-specific activation, melittin was flanked by regions cleavable by matriptase/ST14 (MT), a protease overexpressed in carcinomas. Initial constructs failed due to cytotoxicity during expression, prompting the redesign of melittin into a variant named Pmod2-2. This peptide retained potent pore-forming ability and was compatible with IgG fusion. The resulting scIgG-Pmod2-2 hybrid preserved Fab and Fc functionalities of the atezolizumab IgG, displayed favorable pharmacokinetics and released the active peptide in response to MT. These results highlight the potential of integrating cytolytic PFPs into antibody-based therapeutics.

11 March 2025 in Virus Evolution
Verified
Journal Article
Open access
MÁMiguel Álvarez-Herrera
Miguel Álvarez-Herrera
PRPaula Ruiz-Rodriguez
Paula Ruiz-Rodriguez
BNBeatriz Navarro-Domínguez
Beatriz Navarro-Domínguez
JZJoao Zulaica
Joao Zulaica
BGBrayan Grau
Brayan Grau
MCMireia Coscollá
Mireia Coscollá
Mutations within the N-terminal domain (NTD) of the spike (S) protein are critical for the emergence of successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral lineages. The NTD has been repeatedly impacted by deletions, often exhibiting complex and dynamic patterns, such as the recurrent emergence and disappearance of deletions in dominant variants. This study investigates the influence of repair of NTD lineage-defining deletions found in the BA.1 lineage (Omicron variant) on viral success. We performed comparative genomic analyses of >10 million SARS-CoV-2 genomes from the Global Initiative on Sharing All Influenza Data (GISAID) EpiCov database to evaluate the detection of viruses lacking S:ΔH69/V70, S:ΔV143/Y145, or both. These findings were contrasted against a screening of publicly available raw sequencing data, revealing substantial discrepancies between data repositories, suggesting that spurious deletion repair observations in GISAID may result from systematic artifacts. Specifically, deletion repair events were approximately an order of magnitude less frequent in the read-run survey. Our results suggest that deletion repair events are rare, isolated events with limited direct influence on SARS-CoV-2 evolution or transmission. Nevertheless, such events could facilitate the emergence of fitness-enhancing mutations. To explore potential drivers of NTD deletion repair patterns, we characterized the viral phenotype of such markers in a surrogate in vitro system. Repair of the S:ΔH69/V70 deletion reduced viral infectivity, while simultaneous repair with S:ΔV143/Y145 led to lower fusogenicity. In contrast, individual S:ΔV143/Y145 repair enhanced both fusogenicity and susceptibility to neutralization by sera from vaccinated individuals. This work underscores the complex genotype–phenotype landscape of the spike NTD in SARS-CoV-2, which impacts viral biology, transmission efficiency, and immune escape potential, offering insights with direct relevance to public health, viral surveillance, and the adaptive mechanisms driving emerging variants.

24 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MÁMiguel Álvarez-Herrera
Miguel Álvarez-Herrera
PRPaula Ruiz-Rodriguez
Paula Ruiz-Rodriguez
BNBeatriz Navarro-Domínguez
Beatriz Navarro-Domínguez
JZJoao Zulaica
Joao Zulaica
BGBrayan Grau
Brayan Grau
MCMireia Coscollá
Mireia Coscollá
Mutations within the N-terminal domain (NTD) of the spike (S) protein are critical for the emergence of successful SARS-CoV-2 viral lineages. The NTD has been repeatedly impacted by deletions, often exhibiting complex and dynamic patterns, such as the recurrent emergence and disappearance of deletions in dominant variants. This study investigates the influence of repair of NTD lineage-defining deletions found in the BA.1 lineage (Omicron variant) on viral success. We performed comparative genomic analyses of more than 10 million SARS-CoV-2 genomes from GISAID to decipher the transmission success of viruses lacking S:ΔH69/V70, S:ΔV143/Y145, or both. These findings were contrasted against a screening of publicly available raw sequencing data, revealing substantial discrepancies between data repositories, suggesting that spurious deletion repair observations in GISAID may result from systematic artifacts. Specifically, deletion repair events were approximately an order of magnitude less frequent in the read-run survey. Our results suggest that deletion repair events are rare, isolated events with limited direct influence on SARS-CoV-2 evolution or transmission. Nevertheless, such events could facilitate the emergence of fitness-enhancing mutations. To explore potential drivers of NTD deletion repair patterns, we characterized the viral phenotype of such markers in a surrogate in vitro system. Repair of the S:ΔH69/V70 deletion reduced viral infectivity, while simultaneous repair with S:ΔV143/Y145 led to lower fusogenicity. In contrast, individual S:ΔV143/Y145 repair enhanced both fusogenicity and susceptibility to neutralization by sera from vaccinated individuals. This work underscores the complex genotype-phenotype landscape of the spike NTD in SARS-CoV-2, which impacts viral biology, transmission efficiency, and immune escape potential, offering insights with direct relevance to public health, viral surveillance, and the adaptive mechanisms driving emerging variants.

1 January 2023 in Journal of Infection
Verified
Journal Article
Closed access
JCJorge Camacho
Jorge Camacho
JZJoao Zulaica
Joao Zulaica
EGEstela Giménez
Estela Giménez
LRLuciana Rusu
Luciana Rusu
SASebastian Velandia Alvarez
Sebastian Velandia Alvarez
DNDavid Navarro
David Navarro